Regulatory Aspects of Quality of Life

  • Clare Gnecco
  • Peter A. Lachenbruch


We discuss some issues in using quality of life endpoints in studies that will lead to an application to license a product or add an indication to an already licensed product. Studies of this sort should be double blinded, randomized and use validated questionnaires. The duration of the study should be appropriate for the indication. Missing values can be a serious problem and plans for handling them should be included. Sensitivity analyses are important in this context. An example of a sensitivity analysis shows how substitutions for missing values can offer insight into the effect of these missing values. An alternative model is given to analyze data of this sort. Other analytic methods are discussed in the second part of the paper. The views and opinions expressed in this paper are those of the authors and do not necessarily represent those of the Food and Drug Administration.


Last Observation Carry Forward Miss Data Mechanism Missingness Mechanism Miss Data Imputation Pattern Mixture Model 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Berkanovic, E. and Hurwicz, M.L. (1990). Rheumatoid arthritis and comorbidity. Journal of Rheumatology 17, 888–892.PubMedGoogle Scholar
  2. DeMetri, G.D., Kris, M., Wade, J., Degos, L. and Cella, D. (1998). Quality-of-life benefit in chemotherapy patients treated with epoetin alpha is independent of disease response or tumor type: results from a prospective community oncology study. Journal of Clinical Oncology 16, 3412–3425.PubMedGoogle Scholar
  3. Hurwicz, M.L. and Berkanovic, E. (1993). The stress process in rheumatoid arthritis. Journal of Rheumatology 20, 1836–1844.PubMedGoogle Scholar
  4. Lachenbruch, P.A. (2000). Comparisons of two-part models with competitors. Statistics in Medicine 20, 1215–1234.CrossRefGoogle Scholar
  5. Little, R.J.A. (1993). Pattern mixture models for multivariate incomplete data. Journal of the American Statistical Association 88, 125–134.Google Scholar
  6. Little, R.J.A. (1995). Modeling the drop-out mechanism in repeated-measures studies. Journal of the American Statistical Association 90, 1112–1121.CrossRefGoogle Scholar
  7. Schluchter, M.D. (1992). Methods for the analysis of informatively censored longitudinal data. Statistics in Medicine 11, 1861–1870.PubMedCrossRefGoogle Scholar
  8. Staquet, M.J., Hays, R.D. and Fayers, P.M., eds. (1998). Quality of Life Assessment in Clinical Trials: Methods and Practice. Oxford: Oxford University Press.Google Scholar
  9. Zeger, S.L., Liang, K.Y. and Albert, P.S. (1988). Models for longitudinal data: a generalized estimating equations approach. Biometrics 44, 1049–1060.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2002

Authors and Affiliations

  • Clare Gnecco
    • 1
  • Peter A. Lachenbruch
    • 1
  1. 1.U. S. Food and Drug AdministrationCenter for Biologics Evaluation and ResearchUSA

Personalised recommendations